Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience, Inc. went public on February 1, 2024. Over the last 12 months, the stock price has increased significantly, and as of March 27, 2026, the share price was $20.49. In March 2026, Alto Neuroscience announced a $120 million private placement financing and reported its full-year 2025 financial results. In February 2026, Alto announced the completion of enrollment in the Phase 2 proof-of-concept trial for ALTO-101 in CIAS. In October 2025, ALTO-101 was granted FDA Fast Track Designation for CIAS. In June 2025, Alto acquired ALTO-207, a drug candidate for Treatment-Resistant Depression.

As a clinical-stage biopharmaceutical company, Alto Neuroscience, Inc. does not currently have discernible demand seasonality for its products and services. Demand for future products will likely be driven by medical need and treatment efficacy rather than seasonal patterns.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company in the United States focused on redefining psychiatry through neurobiology to create personalized treatments for neuropsychiatric disorders. The company uses its Precision Psychiatry Platform™ to measure brain biomarkers and match patients with specific investigational therapies. Its pipeline includes product candidates like ALTO-100 for bipolar depression, ALTO-300 for major depressive disorder, ALTO-101 for cognitive impairment associated with schizophrenia, ALTO-203 for MDD with anhedonia, ALTO-202 for MDD, ALTO-207 for treatment-resistant depression, and ALTO-208 for Parkinson's disease.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States and its corporate headquarters are located in Mountain View, California.

Alto Neuroscience's brand reputation is shaped by its scientific advancements and financial activities. The FDA Fast Track Designation for ALTO-101, the acquisition of ALTO-207, positive analyst ratings, a successful IPO, funding from the Wellcome Trust, and strengthened intellectual property have positively affected its reputation. There is no readily available information suggesting significant negative events that have affected Alto Neuroscience's brand reputation in the past year.

The ownership structure of Alto Neuroscience, Inc. includes institutional investors, insiders, and retail investors. Major institutional owners include Falcon Edge Capital, LP, Vestal Point Capital, LP, and Commodore Capital Lp, among others. Amit Etkin, the Founder, Chairman of the Board, and Chief Executive Officer, holds a significant individual ownership stake.